SCHEMBL4377150

SCHEMBL4377150

O=C(O)C(Cc1ccccc1)N1C(=O)/C(=C/c2ccc(-c3ccc(Br)cc3)s2)NC1=S

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ BCL2L2 Q92843 4/20 0.52
▸ BCL2 P10415 1/20 0.52
▸ BAD Q92934 1/20 0.52
▸ PRF1 P14222 4/20 0.49
▸ PTPN1 P18031 2/20 0.46
▸ MCL1 Q07820 1/20 0.45
▸ MAPT P10636 5/20 0.44
▸ ALDH1A1 P00352 4/20 0.42
▸ MEN1 O00255 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ POLB P06746 2/20 0.42
▸ CTSL P07711 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ MME P08473 2/20 0.41
▸ PLA2G1B P04054 1/20 0.41
▸ ATG4B Q9Y4P1 1/20 0.41
▸ GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13587018 1.00 BCL2L2 (0.52) BCL2L2BCL2BADPRF1PTPN1
SCHEMBL1133685 1.00 BCL2L2 (0.52) BCL2L2BCL2BADPRF1PTPN1
SCHEMBL1133613 0.91 PRF1 (0.49) BCL2L2BCL2BADPRF1MAPT
SCHEMBL13587021 0.91 PRF1 (0.49) BCL2L2BCL2BADPRF1MAPT
SCHEMBL1133612 0.91 PRF1 (0.49) BCL2L2BCL2BADPRF1MAPT
SCHEMBL1133775 0.91 PRF1 (0.49) BCL2L2BCL2BADPRF1PTPN1
SCHEMBL1133776 0.91 PRF1 (0.49) BCL2L2BCL2BADPRF1PTPN1
SCHEMBL13587022 0.91 PRF1 (0.49) BCL2L2BCL2BADPRF1PTPN1
SCHEMBL4380766 0.89 BCL2 (0.42) BCL2L2BCL2BADPRF1PTPN1
SCHEMBL1134044 0.89 BCL2 (0.42) BCL2L2BCL2BADPRF1PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2285802-B1 OXO-IMIDAZOLYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY ASTEX PHARMACEUTICALS INC (US) 2015-11-11 — — EP disclosed
US-8759384-B2 Oxo-imidazolyl compounds ASTEXPHRMACEUTICALS, INC. 2014-06-24 — — US disclosed
US-20140073639-A1 INHIBITION OF ANTIMICROBIAL TARGETS WITH REDUCED POTENTIAL FOR RESISTANCE THE ROCKEFELLER UNIVERSITY (US) 2014-03-13 — — US disclosed
US-20090298900-A1 Oxo-Imidazolyl Compounds ASTEXPHRMACEUTICALS, INC. 2009-12-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298900-A1 Oxo-Imidazolyl Compounds GALE, CYP51A1, GNE BCL2L2 3036/4885BCL2 3457/4885BAD 4199/4885
US-20140073639-A1 INHIBITION OF ANTIMICROBIAL TARGETS WITH REDUCED POTENTIAL FOR RESISTANCE GALE, ENGASE, MGAM BCL2L2 3376/4885BCL2 3044/4885BAD 3278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback